title: [Analysis of Anti-VEGF Intravitreal Injection Treatment in Clinical Practice].
abstract: BACKGROUND
  As AMD patients are very often administered intravitreal operative drugs (IVOM), the relevant procedure in ophthalmological institutes was examined in the present project: A questionnaire was used to collect data on structures, criteria and time expended in the treatment in single or small practices, clinics and (university) departments of ophthalmology. 42 facilities participated in the main study.
  
  
  RESULTS
  The patient is usually given an appointment within two weeks of the first contact. If the patient has AMD requiring treatment, the first IVOM is administered within up to two weeks. This often lasts no longer than three hours. The follow-ups after the injection cycle may last up to one hour. If the findings are stable, there is normally a new follow-up after four weeks. The criterion for retreatment is always given as SD-OCT, followed by vision and funduscopy. The next appointment for injection is normally within one week. In diagnostic testing, angiography is almost as important as SD-OCT, funduscopy and vision, but is rarely used as a criterion for retreatment. The main differences in the organisation of the treatment plan are in the time course of the first IVOM and the follow-ups after the injection cycle. In this respect, practice clinics and individual or group practices may be quicker than departments of ophthalmology. One third of the surveyed facilities stated that they cooperated in diagnostic testing. These cooperating facilities repeat many investigations, both in diagnostic testing and in follow-ups.
  
  
  CONCLUSIONS
  Bearing in mind that IVOM patients have a special interest in timely treatment, it would be desirable to shorten the waiting times, both for injection appointments and during treatment. Cooperation between the different service providers is sensible if this shortens the treatment pathways and relieve the patient and ophthalmologist. Moreover, both groups could benefit from standard and efficient treatment pathways, as these simplify patient care, increase the patient's satisfaction with the treatment and therefore tend to increase compliance.
authors.affiliation: AMD-Netz, Münster.
authors.forename: J
authors.initials: J
authors.lastname: Bouws
authors.affiliation: Augenärzte am St. Franziskus-Hospital, Münster.
authors.forename: D
authors.initials: D
authors.lastname: Pauleikhoff
authors.affiliation: Augenarztpraxis Lemmen-Vahdat, Düsseldorf.
authors.forename: K D
authors.initials: KD
authors.lastname: Lemmen
authors.affiliation: Augenärzte am St. Franziskus-Hospital, Münster.
authors.forename: B
authors.initials: B
authors.lastname: Heimes
authors.affiliation: Lehrstuhl für Betriebswirtschaftslehre, insb. Controlling, Westfälische Wilhelms-Universität Münster.
authors.forename: C
authors.initials: C
authors.lastname: Adolphs
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods / Q000706:statistics & numerical data*; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D058449:Intravitreal Injections / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D015995:Prevalence; D012307:Risk Factors; D061665:Time-to-Treatment; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A